Statement: There were 7 more cases of Anaemia and 1 more case of Disseminated intravascular coagulation in cohort 1 of the primary trial compared to cohort 2.
Primary_evidence: Adverse Events 1:   Total: 158/482 (32.78%)   Anaemia 7/482 (1.45%)   Disseminated intravascular coagulation 1/482 (0.21%)   Lymphadenopathy 0/482 (0.00%)   Neutropenia 0/482 (0.00%)   Thrombocytopenia 2/482 (0.41%)   Anaemia 28/482 (1.66%)   Disseminated intravascular coagulation 21/482 (0.21%)   Febrile neutropenia 21/482 (0.21%)   Lymphadenopathy 20/482 (0.00%)   Neutropenia 20/482 (0.00%) Adverse Events 2:   Total: 37/238 (15.55%)   Anaemia 2/238 (0.84%)   Disseminated intravascular coagulation 0/238 (0.00%)   Lymphadenopathy 1/238 (0.42%)   Neutropenia 1/238 (0.42%)   Thrombocytopenia 0/238 (0.00%)   Anaemia 22/238 (0.84%)   Disseminated intravascular coagulation 20/238 (0.00%)   Febrile neutropenia 21/238 (0.42%)   Lymphadenopathy 21/238 (0.42%)   Neutropenia 21/238 (0.42%)